Alectinib + Vismodegib + Ipatasertib + Olaparib + Erlotinib + Bevacizumab + Vemurafenib + Cobimetinib + Trastuzumab Subcutaneous (SC) + Pertuzumab + Atezolizumab + Carboplatin + Paclitaxel + Cisplatin + Gemcitabine + Entrectinib + Ivosidenib + Pemigatinib
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cancer of Unknown Primary Site
Conditions
Cancer of Unknown Primary Site
Trial Timeline
Jul 10, 2018 → Nov 7, 2024
NCT ID
NCT03498521About Alectinib + Vismodegib + Ipatasertib + Olaparib + Erlotinib + Bevacizumab + Vemurafenib + Cobimetinib + Trastuzumab Subcutaneous (SC) + Pertuzumab + Atezolizumab + Carboplatin + Paclitaxel + Cisplatin + Gemcitabine + Entrectinib + Ivosidenib + Pemigatinib
Alectinib + Vismodegib + Ipatasertib + Olaparib + Erlotinib + Bevacizumab + Vemurafenib + Cobimetinib + Trastuzumab Subcutaneous (SC) + Pertuzumab + Atezolizumab + Carboplatin + Paclitaxel + Cisplatin + Gemcitabine + Entrectinib + Ivosidenib + Pemigatinib is a phase 2 stage product being developed by Roche for Cancer of Unknown Primary Site. The current trial status is completed. This product is registered under clinical trial identifier NCT03498521. Target conditions include Cancer of Unknown Primary Site.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03498521 | Phase 2 | Completed |
Competing Products
20 competing products in Cancer of Unknown Primary Site
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| E7389 | Eisai | Phase 1 | 33 |
| Veliparib | AbbVie | Phase 2 | 52 |
| AK-105 | Akeso | Phase 1 | 32 |
| XL820 | Exelixis | Phase 1 | 30 |
| Lymphoseek | Navidea Biopharmaceuticals | Phase 3 | 69 |
| Lymphoseek | Navidea Biopharmaceuticals | Phase 3 | 69 |
| ALT-P7 (HM2-MMAE) | Alteogen | Phase 1 | 33 |
| pegylated liposomal doxorubicin (PLD) + PD-1 | CSPC Pharmaceutical Group Limited | Phase 2 | 51 |
| Biomarkers blood, urine and microbiota samples | Eli Lilly | Pre-clinical | 23 |
| gemcitabine + paclitaxel + bevacizumab | Eli Lilly | Phase 2 | 52 |
| pemetrexed | Eli Lilly | Phase 2 | 52 |
| LY3300054 + Prexasertib | Eli Lilly | Phase 1 | 33 |
| BBP-398 with nivolumab | BridgeBio Pharma | Phase 1 | 30 |
| Cetuximab + Oxaliplatin + Capecitabine | Eli Lilly | Phase 2 | 52 |
| Necitumumab + Gemcitabine + Carboplatin | Eli Lilly | Phase 2 | 52 |
| Gemcitabine + Adriamycine + Paclitaxel | Eli Lilly | Phase 2 | 52 |
| Selpercatinib | Eli Lilly | Pre-clinical | 23 |
| Pemetrexed + Cisplatin + Placebo + Pemetrexed | Eli Lilly | Phase 3 | 77 |
| NBTXR3 activated by IMRT only + NBTXR3 activated by Brachytherapy & IMRT | Nanobiotix | Phase 1/2 | 36 |
| NBTXR3 | Nanobiotix | Phase 1/2 | 36 |